Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€13.13
Change (%) Stock is Down 0.23 (1.72%)
Volume34,657
Data as of 12/09/16 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
06-Dec-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – November 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Dec. 6, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
01-Dec-2016ERYTECH Presents New Data on GRASPA’s Mechanism of Action at ASH Annual Meeting
LYON, France--(BUSINESS WIRE)--Dec. 1, 2016-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the presentation of promising preliminary data for the Company's lead product candidate, eryaspase, also known as ERY-ASP or under the trade name ... 
 Printer Friendly Version
14-Nov-2016ERYTECH Announces Withdrawal of Its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission
Conference call and webcast scheduled for Tuesday, November 15th at 15:00 pm CET/9:00 am ET Withdrawal of European Marketing Authorization Application (MAA) for eryaspase (GRASPA®); additional data requested by the Committee for Human Medicinal Products (CHMP) will take more time to provide than allowed in the CHMP’s approval procedures Intention to resubmit the MAA mid-2017 LYON, Fran... 
 Printer Friendly Version
14-Nov-2016Erytech: Information related to total number of voting rights and shares composing the share capital – October 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Nov. 14, 2016-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com       ... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top